NCT07489300尚未招募2 期
Benmelstobart in Combination With Anlotinib and Oral Metronomic Cyclophosphamide in the Treatment of Recurrent Epithelial OvariaN, Fallopian Tube, or Primary Peritoneal Cancer
Second Affiliated Hospital, School of Medicine, Zhejiang University0 个研究点目标入组 40 人开始时间: 2026年3月30日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 尚未招募
- 发起方
- 入组人数
- 40
- 主要终点
- progression-free survival (PFS)
研究概览
简要总结
Efficacy and safety of Benmelstobart combined with Anlotinib and oral metronomic Cyclophosphamide in the treatment of recurrent epithelial ovarian cancer, fallopian tube cancer or primary peritoneal cancer (BACON study) in China
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •1.The age on the day of signing the informed consent form is 18 years or older. 2.Eastern Cooperative Oncology Group performance status of 0-1, with the ability to tolerate chemotherapy.
- •3.There is measurable disease according to the RECIST 1.1 or irRECIST criteria. 4.The histological types can be serous, endometrioid, clear cell, mucinous or undifferentialed types of recurrent epithelial ovarian cancer, fallopian tube cancer or primary peritoneal cancer. The original primary tumor needs to be histologically confirmed through the pathological report.
- •5.Participants can be either platinum-sensitive (with a platinum-free interval(PFI) of ≥6 months before the recent recurrence) or platinum-resistant (with a PFI of <6 months before the recent recurrence). If the participant has a platinum-sensitive disease, they can only participate in this clinical trial with platinum-based chemotherapy contraindications (such as severe persistent toxicity or a severe hypersensitivity reaction to platinum drugs, or refuse standard treatment).
- •6.The participants must be willing to undergo hollow needle biopsy or excisional biopsy of tumor lesion within 4 weeks (28 days) before the start of the treatment and after 3 cycles treatment. For participants who are unable to provide new samples (for example, unable to obtain or there are issues related to the safety of the participants), only with the consent of the principal investigator can archived samples be submitted.
排除标准
- 未提供
结局指标
主要结局
progression-free survival (PFS)
时间窗: from enrollment to the end of treatment at 2 years
24 months progression-free survival rate will be estimated, and 95% confidence intervals will be calculated.
次要结局
- CRR(6 months)
- OS(5 years)
- AEs(12 months)
研究者
相似试验
尚未招募
3 期
Anlotinib Plus Immunotherapy and Chemoradiotherapy for High-Risk Nasopharyngeal CarcinomaNCT07385079Sun Yat-sen University412
尚未招募
不适用
A Phase II Study of Anlotinib and Platinum-Based Chemotherapy in Patients With SMARCA4-Deficient, Locally Advanced or Metastatic Lung Cancer.NCT07307443Zhijie Wang28
招募中
2 期
A Study of Bemosubaiabimab Combined With Anlotinib and Radiotherapy and Chemotherapy for the Treatment of Oligometastatic Esophageal CancerEsophageal CancerNCT07455019The First Affiliated Hospital with Nanjing Medical University28
招募中
3 期
Becotatug Vedotin Plus Sintilimab in Locoregionally Advanced NPCNCT07459296First Affiliated Hospital of Guangxi Medical University266
招募中
1 期
Testing the Investigational Medication Combination of Teclistamab and Pomalidomide Compared to the Usual Treatment (Carfilzomib, Pomalidomide, and Dexamethasone) for Patients With Multiple Myeloma Who Have Relapsed Shortly After TreatmentNCT07463807National Cancer Institute (NCI)162